Emmaus Life Sciences, Inc. Operating Income Loss

• Emmaus Life Sciences, Inc. showed an increase of +112.2% in Operating Income Loss from 2024 to 2025.
• This data is from Emmaus Life Sciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
• XBRL data for this metric is available from 2011 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 16 years of available data (2011 to 2025), Emmaus Life Sciences, Inc.'s Operating Income Loss has grown by 104.4%.
• Historical annual values: Fiscal year 2025: $231.0 thousand | Fiscal year 2024: -$1.89 million | Fiscal year 2023: $3.54 million | Fiscal year 2022: -$6.59 million | Fiscal year 2021: -$6.13 million | Fiscal year 2020: -$32.0 thousand | Fiscal year 2019: -$4.51 million | Fiscal year 2018: -$8.45 million | Fiscal year 2018: -$10.24 million | Fiscal year 2017: -$7.10 million | Fiscal year 2016: -$3.77 million | Fiscal year 2015: -$2.65 million | Fiscal year 2014: -$3.82 million | Fiscal year 2013: -$4.20 million | Fiscal year 2012: -$4.81 million | Fiscal year 2011: -$5.29 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026